Updates are available Correction dated 2023-06-22
Click to view Correction: https://doi.org/10.1038/s41386-023-01618-z
-
Authors
Murphy, Nicholas https://orcid.org/0000-0003-1805-3082
Tamman, Amanda J. F. https://orcid.org/0000-0002-3620-6698
Lijffijt, Marijn
Amarneh, Dania
Iqbal, Sidra
Swann, Alan
Averill, Lynnette A. https://orcid.org/0000-0002-8985-9975
O’Brien, Brittany
Mathew, Sanjay J.
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (CX-001205-01AI)
- License Information
-
More Information
Article History
Received: 30 November 2022
Revised: 3 April 2023
Accepted: 5 April 2023
First Online: 19 April 2023
Change Date: 22 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41386-023-01618-z
Competing interests
: SJM has served as a consultant to Allergan, Alkermes, Almatica, Axsome Therapeutics, Biohaven, BioXcel Therapeutics, Clexio Biosciences, Eleusis, EMA Wellness, Engrail Therapeutics, Greenwich Biosciences, Intra-Cellular Therapies, Janssen, Levo Therapeutics, Perception Neurosciences, Neurocrine, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Signant Health, and Sunovion. He has served as an investigator for studies funded by Boehringer-Ingelheim, Janssen, Merck, Neurocrine, NeuroRx, and Sage Therapeutics, and has received research support from Biohaven Pharmaceuticals and VistaGen Therapeutics. NM has received research support from Neurocrine. ML has served as principal investigator for trials funded by NeuroRx, VistaGen Therapeutics, Ceruvia Lifesciences, and BrainsWay. ML is currently employed at Sage Therapeutics. The remaining authors have nothing to disclose. LAA has served as a consultant, speaker and/or advisory board member for Guidepoint, Transcend Therapeutics, Source Research Foundation, Reason for Hope, the Cohen Foundation, Beond and Ampelis.
